Back to Authors

Chitnis, Tanuja

0000-0002-9897-4422

A5055725062 | I4210087915

Mayo Clinic

Massachusetts General Hospital

Citations 71

Epigenetic Age is Minimally Correlated with Leukocyte Telomere Length in Pediatric Onset Multiple Sclerosis (P6-1.005)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210880

Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis

Neurology | February 3, 2025 | Volume: 104 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000210213 | PMID 39899789

Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States

Neurology | November 12, 2024 | Volume: 103 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000209991 | PMID 39531607

Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis

Multiple Sclerosis Journal | September 17, 2024 | Volume: 30 | Issue: 11-12 | Pages: 1525-1543

10.1177/13524585241274580 | PMID 39286941

Background and Objectives: This survey study aimed to (1) identify patient/family research priorities in pediatric-onset multiple sclerosis (POMS), and (2) delineate optimized methods for research study/clinical trials design, engagement, and implementation. Methods: Participants were as follows: (1) parents of a child (<18 years) with POMS enrolled in a national registry, (2) adolescents (13–17 years) with POMS in the registry, and (3) adults (18–40 years) with POMS receiving care at a registry affiliated clinic. Of 293 eligible participants, 192 completed surveys. Results: Experiences with health care and medications were generally positive but there remain areas of priority improvement. Incentives to participate in clinical trials included medications previously tested and in pill form, bloodwork/study visits required ⩾ every 3 months, cognitive testing ⩽1 hour, compensation for travel and time, ability to continue current multiple sclerosis (MS) medication, option to take study medication if on placebo, and individualized study feedback. Priorities for clinical research were (1) psychosocial impact, (2) cognitive/academic impact, (3) environmental risk, and (4) nutrition. Conclusions: Results highlighted the importance of a holistic approach to study design and a focus on the impact of disease on daily life to best engage patients and families in POMS clinical trials and research.
Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis

Multiple Sclerosis Journal | July 30, 2024 | Volume: 30 | Issue: 8 | Pages: 1056-1065

10.1177/13524585241261556 | PMID 39078111

Background: Understanding nutrition’s role in multiple sclerosis (MS) can guide recommendations and intervention-based studies. Objective: Evaluate the association between nutrition and pediatric-onset MS outcomes. Methods: Prospective longitudinal multicenter study conducted as part of the US Network of Pediatric MS centers. Predictors were collected using a food screener estimating intake of various dietary food groups (e.g. dairy and fruits) and additional calculated indices (e.g. Healthy Eating Index (HEI)). Outcomes included time-from-enrollment to clinical relapse, new magnetic resonance imaging (MRI) T2 lesions, and Expanded Disability Status Scale (EDSS) increase. Results: 353 children with MS were enrolled (mean ± SD age 15.4 ± 2.9, follow-up 3.9 ± 2.6 years). Multivariable analysis demonstrated that increased dairy by 50% of recommended intake was associated with increased relapse risk by 41% (adjusted hazard ratio (HR) 1.41, 95% CI 1.07–1.86), and risk of T2 progression by 40% (1.40, 1.12–1.74). Increased intake of fruit or vegetable above recommended, and every five-point HEI increase decreased relapse risk by 25% (0.75, 0.60–0.95), 45% (0.55, 0.32–0.96), and 15% (0.84, 0.74–0.96), respectively. No associations were found with EDSS. Conclusion: This work supports the influence of dietary intake on MS course, particularly with dairy intake. Future prospective study is required to establish causation.
Predictors of a Relapsing Course in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (S7.008)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000208303

Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients (P11-6.005)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206450

Pediatric to Adult MS Transition Practices in the US (P1-6.007)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206205

Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US (S51.004)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s51.004

Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s13.003